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Summary.-The relationship between tumour volume response and cell kill in B16
melanoma following treatment in vivo with cyclophosphamide (CY) and 1-(2-
chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) was investigated. Tumour volume
response, expressed as growth delay, was estimated from measurements of tumour
dimensions. Depression of in vitro colony-forming ability of cells from treated
tumours was used as the measure of tumour cell kill. The relationship between these
parameters was clearly different for the two agents studied. CY produced more
growth delay (7-5 days) per decade of tumour cell kill than CCNU (2 to 3-5 days). The
possibility that this was due to a technical artefact was rejected in favour of an
alternative explanation that different rates of cellular repopulation in tumours
treated with CY and CCNU might be responsible. Cellular repopulation was measur-
ed directly, by performing cell-survival assays at various times after treatment with
doses of CY and CCNU which produced about 3 decades of cell kill. The rate of re-
population by clonogenic cells was much slower after treatment with CY than with
CCNU, and this appears to account for the longer duration of the growth delay
obtained with CY.
TUMOUR volume response to cytotoxic
treatment is determined by 3 main factors:
the proportion ofcells killed by treatment,
the rate and extent ofcell loss, and the rate
of repopulation by tumour stem cells
surviving treatment. Although cell kill
may be regarded as the primary factor,
without which there is unlikely to be any
volume regression, differences in the rates
of cellular repopulation after treatment
with various agents will influence the
extent of tumour volume response.
In this paper, we describe experiments
designed to study the relationship between
tumour volume response and cell kill in
B16 melanoma treated with cyclophospha-
mide (CY) and 1-(2-chloroethyl)-3-cyclo-
hexyl-1-nitrosourea (CCNU). CY and
CCNU were chosen for this study because
they showed marked differences in be-
haviour in preliminary experiments per-
formed with various chemothecrapeutic
agents which produce significant e'evels of
cell kill and delay in the growilth of B16
melanoma. Tumour volume resi)onse, ex-
pressed as growth delay, was followed by
caliper measurements. Depression )I the
in vitro colony-forming ability cf cells,
obtained from treated tumouls by tryp-
sinization, was used as the measure of cell
kill. The relationship between growth
delay and surviving fraction differed for
the two agents studied, and the rates of
cellular repopulation, after doses which
produced equivalent levels of measured
cell kill, were compared to see how far the
observed discrepancy could be accounted
for by repopulation differences.
MATERIALS AND METHODS
Drugs.-CY (Endoxana) was obtained in
100-mg vials from Ward Blenkinsop Pharma-T. C. STEPHENS AND J. H. PEACOCK
ceuticals Ltd, Bracknell, England. It was dis-
solved in 0-15M NaCl for i.p. injection and was
always used within 1 h of being prepared.
CCNU was obtained in 40-mg capsules for
human use (National Cancer Institute). The
contents of a capsule were dissolved in 1 ml of
dimethyl sulphoxide and diluted to the
required concentration with 500 Tween 80 in
phosphate-buffered saline (PBS A, Dulbecco
and Vogt, 1954). This mixture was homo-
genized to produce a uniform suspension
which was injected i.p.
Mice and tumours. C57BL mice of either
sex were supplied by the Institute of Cancer
Research breeding centre. They weighed
20-25 g when used for experiments. B16
melanoma was obtained from the Roscoe B.
Jackson Memorial Laboratory, Bar Harbour,
Maine, in 1970. For transplantation, a tumour
brei was prepared as described by Stephens,
Peacock and Steel (1977) and 0*05-ml aliquots
were injected either s.c. into each flank, or
i.m. into the gastrocnemius muscle of each
leg. A few experiments were performed using
Lewis lung carcinoma. The method of trans-
plantation was the same as for B16 melanoma.
Mice were selected for experiments when both
of their tumours were within the size range
0.05 to 0-2 g.
Measurement of tumour size. Measure-
ments of the size of s.c. and i.m. tumours
were made by the calibration curve technique
(Steel, Adams and Barrett, 1966). For s.c.
tumours the product of two superficial
diameters was used as a measure of tumour
size, and for i.m. tumours the mean of two
leg diameters was used. The calibration curves
were constructed by direct studies of the
relationship between these measures and the
weight of tumour on dissection.
Measurement of growth delay.-Tumour-
bearing mice were allocated randomly into
groups of 7 or 8. Each animal was then ear-
marked and its tumours were measured. One
group was selected as untreated controls and
the others were treated with cytotoxic agents
at a range of dose levels. Eighteen hours later
2 animals were taken at random from each
group, tumour cell suspensions were prepared
from the pooled tumours and cell survival
was measured in vitro as described below. The
remaining tumours were measured every 2 or
3 days until they were at least 4 x the size
recorded on the day of drug administration.
The time taken for each individual tumour to
increase in size by a factor of 4 was deter-
mined (T4,). Time to regrow to 4 x the
original volume was used because the agents
used in this study did not usually cause
tumours to regress below their volume at the
time of treatment. With the exception of the
highest dose of CY, tumours had always
returned to their pre-treatment growth rate
during this time (see discussion). Growth
delay was calculated as [median T4X following
treatment - median T4X of untreated con-
trols].
Preparation of cell suspensions.-Cell sus-
pensions were prepared from B16 melanoma
as described previously (Stephens, Peacock
and Steel, 1977). In the case of Lewis lung
carcinoma the method was similar, except
that the duration ofthe second trypsinization
was reduced from 45 to 20 min. The mean cell
yields per gram of tissue obtained from un-
treated tumours were, 1.1 x 108 (s.d.
2-5 x 107, n 24) for s.c. B16 melanoma,
8-7 x 107 (s.d. 1.6 x 107, n 5) for i.m. B16
melanoma and 4-6 x 107 (s.d. 1.8 x 107, n 4)
for Lewis lung carcinoma. In each case vital
staining with erythrosin B indicated viability
>95%.
Microscopic preparations of tumour cells
were made using a cytocentrifuge, and stained
with Giemsa.
Cell survival assay.-Survival of B16
melanoma cells was measured using the soft-
agar-colony assay described by Courtenay
(1976) and modified by Stephens et al. (1977).
Varying numbers of viable cells ranging from
500 to 104 were plated in 30-mm Petri dishes.
The total number of cells plated in each dish
was adjusted to about 104 by the addition of
cells which had been killed by exposure to
30,000 rad of 60Co y-rays (HR cells).
Cultures were incubated for 14 to 16 days at
37°C in a water-saturated atmosphere of 500
C02, 5% 02, and90%o N2. All colonies ofmore
than 50 cells were counted and plating
efficiency (PE) was calculated as (number of
colonies scored)/(number of cells plated). At
least 3 dishes were counted for each experi-
mental point, and the standard error was
usually about 500 of the mean. The PE of
control B16 melanoma cells varied from 0 30
to 0 55 and of Lewis lung carcinoma, from
0415 to 0 40, over the period during which this
work was done. Plating efficiencies down to
0*0005 could be measured by this method.
Response to cytotoxic agents was expressed
in terms of the fraction of surviving cells per
tumour. This was calculated as the product of
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the ratios of treated to corresponding control
values for tumour weight, cell yield per gram
of tissue and PE.
Fraction of surviving cells per tumour=
Surviving fraction x Relative cell yield per g
x Relative tumour weight
RESULTS
Growth delay vs drug dose
Groups of mice bearing s.c. B16 mela-
noma were treated with a range ofdoses of
CY and CCNU. The median times required
for tumours to quadruple in size are
plotted against drug dose in Fig. 1. Un-
treated tumours took about 6 days. At all
doses of CY and CCNU, tumours suffered
some growth delay. The relationship
between median T4X and CY dose was
linear. In the case of CCNU however, the
curve was not linear at doses below 20 mg/
kg, although at higher doses it appeared to
be linear.
Dose-survival studies
The fraction of surviving cells in s.c.
B16 melanoma was measured 18 h after
administration ofCY and CCNU at a range
ofdoses. Theresulting dose-survival curves
are shown in Fig. 2. For both agents, there
appeared to be an exponential relation-
ship, although in the case of CCNU there
was a shoulder at low dose levels. The dose
of CY which reduced cell survival to 10%
of its original value (D1o) was 120 mg/kg,
and over the exponential part ofthe curve,
the D1o for CCNU was 6-5 mg/kg.
An additional experiment was perform-
ed on s.c. B16 melanoma to examine the
possibility that an excess of CY- or
CCNU-killed cells might modifythe in vitro
PE of surviving clonogenic cells. The
results (shown in the Table) indicate that
this does not occur. The PEs obtained
when untreated cells, or those treated with
low doses of CY or CCNU, were plated in
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FIG. I. Median time required for s.c. B16
melanoma to increase in size by a factor of4
(Median T40) plotted as a function of dose
of CY and CCNU. The dose scales for each
agent extend to their approximate LDio
levels. Pooled data from 3 experiments for
each agent are plotted.
FIG. 2. Dose-survival curves for s.c. B16
melanoma treatedl with CY and CCNU.
When growth-delay experiments were per-
formed, additional animals were treated
with drug, and tumour-cell survival was
measure(d 18 h later. The dose scales for
each agent extend to their approximate
LD10 levels. Pooled data from 3 experi-
ments for each agent are plotted.
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TABLE.-Effect of an Excess of C Y- or
CCNU-killed Cells on thePEofSurviving
B16 Melanoma Cells
Cells plated in vitro5
104 CY-killed cellsl
104 CCNU-killed cells2
500 untreated cells
500 untreated cells + 104 CY-
killed cellsl
500 untreated cells + 104
CCNU-killed cells2
1000 CY-treated cells3
1000 CY-treated cells3 + 104
CY-killed cellsl
1000 CCNU-treated cells4
1000 CCNU-treated cells4 + 104
CCNU-killed cells2
20
15
PE
0 0005
s.d.
0 0002 10
0 0008 0 0002 >.
0-619 0 030 -3
0 645 0-057 x
0 659 0 042 <
0
0-105 0 0058 x
0-102 0-0061
0-072 0-0033
0-071 0-0052
5
1 From tumours treated 18 h previously with
300 mg/kg CY.
2 From tumours treated 18 h previously with
20 mg/kg CCNU.
3 From tumours treated 18 h previously with
100 mg/kg CY.
4 From tumours treated 18 h previously with
10 mg/kg CCNU.
5 All platings included 104 cells killed with
30 krad y-rays.
the presence or absence ofa large excess of
cells killed with these agents were not
significantly different.
Growth delay vs cell survival
The comparison of median T4X with cell
survival in s.c. tumours 18 h after drug
administration is shown in Fig. 3. The
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FRACTION OF SURVIVING CELLS PER TUMOUR
FIG. 3.-Relationship between Median T4, and cell survival in s.c. B16 melanoma
treated with CY (0) and CCNU (0) (i.e.
the data obtained in the experiments shown
in Figs 1 and 2 are plotted against each
other).
FRACTION OF SURVIVING CELLS PER TUMOUR
FIG. 4. Relationship between Median T4.
and cell survival in i.m. B16 melanoma
(upper graph) and s.c. Lewis lung carci-
noma (lower) treated with CY ( 0) and
CCNU (0). Experiments were similar to
those described in Figs 1 and 2. The data
from single experiments for each agent are
plotted.
relationships between these parameters
are clearly different for CY and CCNU.
The curve for CY is exponential, the
growth delay being about 7*5 days for
each decade reduction in cell survival. In
the case of CCNU, however, there may be
an upward curvature and the growth
delay per decade reduction in cell survival
appears to range from about 2 to 3-5 days.
Similar experiments were also performed
on B16 melanoma growing in the i.m. site,
and on s.c. Lewis lung carcinoma. The
results are shown in Fig. 4. In both cases,
CY gave a linear relationship between T4X
and cell survival, whilst CCNUgave curves
that were slightly concave upwards.
Cellular repopulation studies
Cellular repopulation in s.c. B16 mela-
nomas treated with CY and CCNU was
studied, using the in vitro cell-survival
assay. Doses of each agent were chosen
which gave about equal (10-3) reductions
in fraction of surviving cells per tumour
18 h afterdrugadministration (CY300 mg/
kg and CCNU 20 mg/kg-see Fig. 2). The
first assay was performed 2 h after drug
administration, with subsequent assays at
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FIG. 5. Growth curves for untreated s.c. B16
melanioma over the size range 0 1 to 15 g.
Pooled data from 2 experiments.
intervals of 1 to 3 days (until the incidence
of tumour ulceration rose sharply).
The growth curve of untreated s.c. B16
melanomas, from about 0-1 g to 1-5 g, is
shown in Fig. 5. The mean tumour weight
(obtained by dissection), total yield ofcells
per tumour (calculated as the product of
tumour weight and cell yield per gram of
tissue trypsinized), and number of clono-
genic cells per tumour (calculated as the
product of tumour weight, cell yield per
gram of tissue trypsinized and PE) all
increased with a doubling time (Td) of
about 2-8 days. Tumours began to ulcerate
when they exceeded a weight of about 1 g.
Cellular repopulation after treatment of
tumour-bearing mice with CY is shown in
Fig. 6. Tumour weight continued to
increase exponentially, but with a doubl-
ing time that was about 9 days. Tumours
began to ulcerate at 0-5 g. The total yield
of cells per tumour fell gradually to about
25% of its initial value in the 8 to 10 days
immediately following drug administra-
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FIG. 6. Cellular repopulation curves for s.c.
B16 melanoma treated with CY at 300 mg/
kg. The first assay was performed 2 h after
treatment, and subsequent assays were
performed at intervals of 1 to 3 days.
Pooled data from 2 experiments.
tion. This was followed by a recovery
phase with a Td of about 3 days. Micro-
scopic examination of cytocentrifuge pre-
parations, made at daily intervals after
treatment with CY, indicated that as the
total cell number decreased the mean cell
volume increased. Mean cell volume reach-
ed a peak of nearly 10 x control level
between Days 6 and 10 after treatment.
Two hours after treatment with CY, the
number of surviving clonogenic cells per
tumour was reduced by about 3 decades
compared to untreated controls. Allowing
for the scatter in the experimental
points, it was apparent that cellular
repopulation was under way by 5 days
after treatment, and between Days 5 and
15 the data are consistent with exponen-
tial repopulation with a doubling time of
about 1-5 days. The data could however
also be consistent with an initial lag period
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of 3 to 4 days followed by a gradual
acceleration in the repopulation rate, a
minimum Td ofabout 1 day being reached
10 to 12 days after treatment. After Day
15, however, the repopulation rate de-
creased, until it was consistent with that of
total cells per tumour (i.e. about 3 days).
Fig. 7 shows cellular repopulation after
treatment with CCNU. Tumour weight
again increased exponentially, but with a
doubling time of 3-6 days (cf. 2-8 days for
untreated control tumours). Tumours
began to ulcerate when they reached about
1 g. During the 4 days immediately after
drug administration, the total number of
cells per tumour fell to about 5000 of its
initial value. This was followed by a fairly
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FIG. 7. Cellular repopulation curves for s.c.
B16 melanoma treated with CCNU at
20 mg/kg. Other details as in Fig. 6.
rapid recovery, and by Day 10 the total
cell number per tumour had reached the
level that would be expected if the cells
initially present had grown with a Td of
about 3'6 days. Cell volume was found to
increase immediately after CCNU admini-
stration, when total cell number was
decreasing. The peak cell volume was
nearly 5 x that of control cells and was
reached on about Day 6. The number of
surviving clonogenic cells per tumour was
reduced by about 3 decades compared to
untreated controls when measurements
were performed 2 h after CCNU admini-
stration. Cellular repopulation appeared to
begin immediately and was very rapid, the
Td being about 0.85 days. However, after
10 days the rate of clonogenic cell re-
population decreased, and the growth of
total cells per tumour and clonogenic cells
pertumour was consistent withthe tumour
volume Td of 3-6 days.
DISCUSSION
The present work has demonstrated
that the relationship between tumour-
growth delay and the extent of cell kill, as
measured by a clonogenic cell assay,
depends on the cytotoxic agent used to
produce damage.
In the B16 melanoma, to achieve a 10-
day growth delay it was necessary to
reduce clonogenic cell survival to less than
10-3 with CCNU, but only to about 10-1
with CY. In the Lewis lung tumour the
difference was in the same direction but
not so great.
Two possible explanations may be
considered. Firstly, a technical artefact
may have led us to false estimates of cell
survival or growth delay, and secondly,
the results may reflect a difference in the
rate of tumour-cell repopulation after
treatment with these drugs.
It has been assumed in this work that
the behaviour ofcells obtained by trypsini-
zation is representative of all cells in an
intact tumour. The possibility that the
PE ofdrug-damaged cells may be modified
by trypsin cannot definitely be ruled out,
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althoughnoevidenceisavailabletosupport
such a suggestion. Two other errors which
might occur in cell-survival measurement
are the influence of drug-damaged cells on
colony growth in vitro and the occurrence
ofa phenomenon such as repair ofpotenti-
ally lethal damage (PLD). The results
shown in the Table seem to rule out the
first of these possibilities. The repair of
PLD after treatment with drugs or radia-
tion has been well described (Little et al.,
1973; Hahn et al., 1973, 1974; Twentyman
and Bleehen, 1975). However, this has
usually been found to be a relatively rapid
process that is complete within 6 to 10 h of
treatment, although, following treatment
ofEMT6 with CY, repair ofPLD may take
up to 48 h (Twentyman, 1977). There is no
evidence in the data shown in Fig. 7 for
such a process occurring in B16 melanoma
after CCNU. The number of clonogenic
cells per tumour increased exponentially
from 2 h to 10 days after treatment, with a
doubling time of 20 h. This is consistent
with a pure repopulation process that
begins immediately after treatment. There
is also no evidence for the repair of PLD
after treatment ofB16 melanoma with CY
(Fig. 6, this paper; also Stephens, Peacock
and Steel, 1977). Further evidence that
PLD repair does not occur after treatment
with either CCNU or CY is available from
the work of Hill and Stanley (1975) who
found that dose-survival curves obtained
2 and 22 h after treatment of B16 mela-
noma with these agents were identical.
A study ofthe curability ofi.m. implants
of small numbers of B16 melanoma cells
also appears to confirm that the cell-
survival data obtained with the in vitro
colony assay is representative of the in
vivo situation. Groups of animals were
implanted with 32 tumour cells and treat-
ed with CY and CCNU several days later.
The TCD5os (drug doses to cure 5000 of
implants) for each agent, which represent
doses which have reduced cell survival by
the same degree, were compared. When
CY and CCNU were administered 2, 3 or 6
days after implantation of tumour cells
the TCD50 ratios were 8-5: 1, 10: 1 and
13'5 : 1 respectively. These ratios compare
well with those calculated from the sur-
vival data presented in Fig. 2 (e.g. ranging
from about 10 1 at a fractional cell-
survival level of 10-1 to about 14: 1 at
10-3). These data will be the subject of a
separate publication.
Significant errors seem unlikely to arise
in the assessment of growth delay by the
method used here. With the exception of
some tumours treated with 300 mg/kg of
CY, growth rate had always returned to
that of untreated tumours well before 4 x
the original weight was reached. Re-
growth to a larger size could not be used,
because tumours beganto ulcerateatabout
0 5 g when treated with high doses of CY.
That the discrepancies between the
results for CY and CCNU might arise from
difference in rates of cellular repopulation
seems much more plausible. The average
rate of repopulation by surviving clono-
genic cells was estimated from the data
presented in Fig. 3. The median time for
tumours to quadruple in volume was
divided by the estimated number of cell
doublings which occurred during recovery.
This number of cell doublings was esti-
mated by assuming (1) that surviving
fraction must return to unity and (2) that
2 extra doublings must be added to take
account of the fact that the end-point of
the experiment was a 4-fold increase in
tumour volume. This calculation probably
underestimates the actual number of
doublings involved, for there may be some
cell loss, or failure to divide, in the re-
growing cell population. The Td obtained
therefore represents a probable maximum
value. The estimated mean Tds are plotted
against the extent of cell kill in Fig. 8. At
cell-survival levels below 10-1 the esti-
mated mean Td for CCNU was about 1 2
days, and that for CY about 2-4 days. At
higher levels ofcell survival, the estimated
mean Td approached the volume-doubling
time of control tumours, which was 3 days
(i.e. T4x/2). Thus it would appear that the
observed results can be explained if cells
repopulate approximately twice as quickly
after treatment with CCNU as with CY.
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The repopulation studies reported here
were found to confirm that cellular re-
population is more rapid after treatment
with CCNU than after CY.
The results presented here emphasize
the complexity ofthe relationship between
tumour-cell kill and growth delay (see also
McNally, 1973,1975a, 1975b; Twentyman,
1977). It would appear that the estimation
of cell kill from tumour-growth delay data
might be very difficult, although this has
been attempted by Lloyd (1975) and by
Griswold (1975). They made the assump-
tion that cellular repopulation after treat-
ment occurs atthe samerate asthegrowth
of an equal-sized population of untreated
cells. This assumption is clearly suspect,
and may explain why Lloyd's estimated
values for cell kill after treatment of B16
melanoma with CCNU and MeCCNU
appeared to be lower than was obtained by
direct bioassay. Griswold's estimates of
cell kill in B16 melanoma following treat-
ment with MeCCNU were also much lower
than the values obtained by Blackett,
Courtenay and Mayer (1975) using a
colony assay. Griswold also obtained much
higher estimates ofcell kill by CY than we
have observed in this study. These results
may be explained, ifthe repopulation rate
assumed by Griswold was underestimated
after MeCCNU treatment but overesti-
mated after CY. The reason for the more
rapid repopulation after treatment with
CCNU than after CY, reported here, is
under investigation. Possible explanations
being considered include inherent changes
following treatment, in the intermitotic
time of surviving cells, the degree of
damage to the tumour matrix, the nutri-
tional status of animals and the immuno-
logical response.
We thank Dr G. G. Steel and Professor
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